EGFR and neoplasm: Finally, we have assessed whether afatinib, a second generation TKI could be used to treat tumor relapse since adding afatinib to osimertinib could help overcome EGFR-dependent osimertinib resistance, such as secondary C797S mutation or other co-existing EGFR mutations [15].